Background: In Japan, no platelet (PLT) additive solutions (PASs) are officially approved for clinical use although blood centers often receive requests for washed PLTs to reduce adverse reactions. Recently, we developed a novel PAS called BRS-A based on clinically available bicarbonated Ringer's solution (BRS), Bicanate and acid-citrate-dextrose formula A (ACD-A), which has been shown to maintain the in vitro properties of PLTs in the condition of <5% residual plasma during 7-day storage. The aim of this study was to evaluate whether another clinically available BRS, Bicarbon with different electrolyte concentrations can be used as a PAS. Study design and methods: Two types of BRS-As were prepared by adding 25 mL of ACD-A to 500 mL of Bicanate or Bicarbon BRSs. Bicanate-based BRS-A and Bicarbon-based BRS-A contain 0.9 or 0.5 mmol/L of magnesium chloride, 95.2 or 100.1 mmol/L of sodium chloride, 4.2 or 5.1 mmol/L of trisodium citrate, and 26.6 or 23.8 mmol/L of sodium bicarbonate, respectively; the other components were identical. Apheresis PLTs stored in these solutions with less than 5% plasma for 7-day storage were compared with regard to their in vitro properties. Results: The pH levels of all units were above 7 throughout storage. The mean PLT volume, hypotonic shock response, glucose consumption, lactate production, swirling, and CD62P and CD42b expression were similar during 7-day storage. The bicarbonate levels in Bicarbonbased BRS-A were lower than those in Bicanate-based BRS-A. Conclusion: Differences in concentrations of electrolytes such as magnesium, sodium, citrate, and bicarbonate salts in BRS-A do not affect the in vitro properties of PLTs during 7-day storage. These results indicate that the use of another type of BRS-A based on Bicarbon as a PAS is feasible. Thus, BRS-A can be used in hospitals that do not stock Bicanate but have Bicarbon.
Introduction
Adverse reactions to platelet (PLT) transfusion such as anaphylaxis and febrile nonhemolytic transfusion reactions are reduced by PLT washing with PLT additive solutions (PASs) to decrease the amount of plasma transfused to recipients [1] . Plasma replacement with PASs has a variety of benefits, including prevention of adverse reactions, recovery of additional plasma for fractionation, and improvement of PLT storage conditions [2] , although the previous study has demonstrated that the PLT washing step reduces the corrected count increment [3] . Currently reported PASs such as T-sol, InterSol, and Composol require 30-40% residual plasma as the source of glucose and bicarbonate [4] . Regarding SSP+, 20% plasma inclusion is enough for general 7-day storage [5] . These residual plasma levels result in approximately 50% reduction of allergic transfusion reactions compared to whole plasma [6] .
In Japan, no PASs are officially approved for clinical use although blood centers often receive requests for washed PLTs to reduce adverse reactions. Therefore, Hirayama et al. developed a glucose-and bicarbonate-containing PAS called M-sol, which is prepared by mixing several clinical infusions and can preserve the in vitro properties of PLTs in the condition of <5% residual plasma during at least 7-day storage [7] . PLTs suspended in M-sol with >90% plasma reduction eliminated the broad spectrum of adverse reactions caused by PLTs in 100% plasma [8, 9] . Recently, Radwanski et al. developed PAS-5, which is based on PAS-III with additional salts, bicarbonate, and glucose. PLTs suspended in PAS-5 with 5% plasma maintained the in vitro properties of PLTs during 7-day storage [10] . More recently, we developed a novel PAS called BRS-A based on clinically available bicarbonatebuffered Ringer's solution (BRS) (Bicanate; Otsuka Pharmaceutical Factory, Inc., Tokushima, Japan) and acidcitrate-dextrose formula A (ACD-A), which has been shown to maintain the in vitro properties of PLTs in the condition of <5% residual plasma during 7-day storage [11] . M-sol and BRS-A are listed in the Japan Society of Transfusion Medicine and Cell Therapy guidelines issued in 2013 [12] .
Another clinically available BRS, Bicarbon (AY Pharmaceuticals Co., Ltd., Tokyo, Japan), which is similar to Bicanate in that it contains magnesium, potassium, and calcium salts in addition to other electrolytes and is widely supplied as a useful infusion fluid in Japan. Both Bicanate and Bicarbon are supplied in a plastic bag containing a gas-barrier film to maintain pH stability by preventing CO2 leakage. These two BRSs differ in their concentrations of magnesium, sodium, citrate, and bicarbonate, and it is unclear whether the difference can affect the in vitro properties of PLTs when these BRSs are applied as a PAS. The aim of this study was to compare the in vitro properties of PLTs stored in BRS-A prepared using these two BRS types with different electrolyte concentrations.
Methods

Preparation of BRS-A
Bicanate (Otsuka Pharmaceutical Factory, Inc.) containing (per 500 mL) 2.92 g of NaCl, 0.15 g of KCl, 0.11 g pf CaCl2·2H2O, 0.10 g of MgCl2·6H2O, 1.175 g of NaHCO3, and 0.10 g of Na3-citrate·2H2O and Bicarbon (AY Pharmaceuticals Co., Ltd.) containing (per 500 mL) 3.07 g of NaCl, 0.15 g of KCl, 0.11 g of CaCl2·2H2O, 0.0510 g of MgCl2·6H2O, 1.05 g of NaHCO3, and 0.245 g of Na3-citrate·2H2O were used to prepare BRS-A. Immediately prior to PLT washing, BRS-A was prepared by adding 25 mL of ACD-A (Kawasumi Laboratories, Inc., Tokyo, Japan) to 500 mL of Bicanate or Bicarbon. Bicanate-based BRS-A and Bicarbon-based BRS-A were designated as the control and test preparations, respectively ( Table 1) . After gentle mixing, the solutions were sterilized using a sterile isolation bag with the integrated 0.22μm filter (KBP-1000F; Kawasumi Laboratories, Inc., Tokyo, Japan).
PLT washing
White blood cell-reduced apheresis PLT concentrates (PCs) had been rejected for clinical use because of higherthan-permitted alanine aminotransferase levels. PCs were stored at 20-24°C on a flatbed agitator (60 cycles/min) and washed within 2 days after collection. After two ABOidentical PCs were mixed, the sample was divided equally between the control and test units. For PLT washing, 250 mL of BRS-A and 25 mL of ACD-A were added to PCs, and the mixture was centrifuged at 1500 × g for 20 min at 22°C. The supernatant was removed using a manual hand press (separation stand, Kawasumi Laboratories), and BRS-A was added to achieve a final washed PLT volume of 200 mL. PLT pellets were allowed to rest for 30 min and then resuspended in polyolefin bags (KBP-1000FPN, Kawasumi Laboratories) with agitation at 60 cycles/min for 30 min at 20-24°C.
In vitro testing
Sampling was performed before and after PLT washing and on days 1, 3, 5, and 7 of storage via sterile connection in 80-mL sterile isolation bags (BB-T008FJ; Terumo Corporation, Tokyo, Japan). Plasma protein levels in PCs before and after washing were measured by the bicinchoninic acid assay (BCA protein assay kit, Pierce, Rockford, IL, USA) and used to determine the protein removal ratio. Total PLTs were counted to determine PLT recovery. PLT count and mean PLT volume (MPV) were measured using an automated blood cell counter (KX-21; Sysmex Corporation, Kobe, Japan). The Table 1 Composition of platelet additive solutions (mmol/L). levels of pH, pO2, and pCO2 were measured using an automatic blood gas analyzer (ABL5; Radiometer, Copenhagen, Denmark) at 37°C. The level of bicarbonate was automatically calculated from these variables. To determine glucose and lactate levels, PLT samples were pelleted by centrifugation at 10,000 × g for 5 min at 22°C, and the supernatant was stored at −40°C until use; glucose and lactate were assessed by colorimetric assays using a commercially available Glucose CII Test (Wako Pure Chemical Industries, Ltd., Osaka, Japan) and L-lactic acid kit (Roche Diagnostics, GmbH, Mannheim, Germany), respectively. Swirling was assessed by visual inspection and graded as 0 (no swirling), +, ++, or +++ (maximum swirling). To measure the hypotonic shock response (HSR), the PLT concentration in the samples was adjusted to 300 × 10 9 /L with AB plasma [13] . HSR was determined as previously described [14] . Expressions of the PLT surface markers, CD62P (P-selectin) and CD42b (GPIbα), were analyzed by flow cytometry as described previously [11] . All antibodies were purchased from BD Bioscience-Pharmingen (San Jose, CA, USA).
Bicanate-based BRS-A Control
Statistical analysis
The data are presented as the mean ± standard deviation (SD). Statistical analysis was performed with MS Excel 2013 software (Microsoft Corporation, Redmond, WA, USA). The differences between the control and test units were determined by two-tailed Student's t-test and were considered statistically significant at P < 0.05.
Results
The concentrations of NaCl, MgCl2, trisodium citrate, and NaHCO3 differed between the control and test BRS-A (Table 1 ). In the control and test units, the plasma removal ratio was 98.5 ± 0.2% and 98.4 ± 0.2% and the PLT recovery was 91.7 ± 1.6% and 92.6 ± 1.0%, respectively (n = 6). On the day of washing, the PLT count (×10 9 /L) of the control and test units was 1035 ± 39 and 1059 ± 45, and the volumes (mL) of the control and test units were 202.9 ± 1.4 and 203.0 ± 1.6, respectively (n = 6).
The pH levels were above 7.0 (7.13-7.47) in all units during 7-day storage. The pH levels in the test units on days 5 and 7 were lower than those in the control units ( Table 2) . On day 5, the pO2 levels in the test unit were significantly lower than that in the control unit ( Table 2 ). Significant differences in bicarbonate levels were observed between the control and test units during 7-day storage ( Table 2) . Glucose consumption and lactate production were estimated from day 1 up to day 3 because of glucose exhaustion and cessation of lactate production by day 5 (Table 2) ; the rates in the test units were comparable to those in the control units: 1.45 ± 0.16 versus 1.45 ± 0.17 mmol/10 12 PLTs/day, respectively, for glucose consumption, and 2.47 ± 0.36 versus 2.59 ± 0.44 mmol/10 12 PLTs/day, respectively, for lactate production. Bicarbonate neutralization rates of the test units on days 1-7 were comparable to those of the control units (1.14 ± 0.07 mmol/10 12 PLTs/day versus 1.14 ± 0.07 mmol/ 10 12 PLTs/day).
Swirling was well maintained in all units throughout storage (Table 3 ). No differences in HSR, MPV, and CD62P and CD42b expressions were observed during 7-day storage ( Table 3 ).
Discussion
In this study, we used a bicarbonate-buffered acetatefree PAS, BRS-A, prepared using two types of clinically available BRSs (Bicanate and Bicarbon) with different concentrations of electrolytes such as magnesium, sodium, citrate, and bicarbonate salts as a synthetic storage medium for washed PLTs. The in vitro properties of PLTs (pH, pCO2, pO2, bicarbonate, MPV, glucose and lactate concentration, HSR, CD62P and CD42b expression, and swirling) during 7-day storage showed similar levels in the control and test units. Given that our previous study demonstrated that the in vitro properties of PLTs stored in Bicanate-based BRS-A were superior to those stored in plasma [11] , the results of this study indicate that another type of BRS-A based on Bicarbon, which has different electrolyte concentrations, can be used as a PAS.
Previous reports demonstrated that low PLT recovery was related to residual PLT clumps formed during the washing process [15, 16] . In contrast, in this study the recovery exceeded 90% in the control and test BRS-As. The addition of ACD-A together with BRS-A to PCs prior to centrifugation may have facilitated the resuspension of the PLT pellet. In our washing procedure, the difference in medium constituents did not seem to affect the time of PLT pellet resuspension and plasma protein removal.
Bicarbonate has not been shown to support in vitro PLT functions during storage; however, it is essential for maintaining the pH of PASs [17] , as it can inhibit pH decline through decomposition of lactate produced by glucose consumption. Although the slight difference in bicarbonate level between the control and test units was reflected in pH levels, these were consistently maintained above 7.0 in all units. BRS-A is an acetate-free PAS ( Table 1 ). In PLTs, acetate enters the tricarboxylic acid cycle and is further oxidized in the respiratory chain to produce ATP [18] . Accordingly, acetate in PASs has been shown to decrease lactate production by reducing the rate of glycolysis [19] . Another important role of acetate in PASs is to maintain stable pH levels through conversion to bicarbonate [19, 20] . The result of this study indicates that BRS-As contain sufficient bicarbonate to maintain stable pH levels without acetate.
No significant differences in glucose consumption and lactate production were observed ( Table 2 ). These facts indicate that glucose consumption and lactate production were unaffected by different electrolyte concentrations of BRS-As (Table 1) .
We also assessed the expression of the PLT surface glycoproteins CD42b and CD62P. CD42b is an adhesion receptor on the PLT surface membrane that binds to the von Willebrand factor (vWF) and facilitates PLT adhesion to the vascular subendothelium after vascular injury. CD62P translocation from intracellular alpha-granule membranes to the PLT surface membrane is accompanied by PLT activation [21] , suggesting that CD62P is an indicator of activated PLTs. Furthermore, the surface expression of CD62P and CD42b is associated with PLT clearance [22] . The similarity in CD62P and CD42b expression in the control and test units indicates that differences in magnesium, sodium, citrate, and bicarbonate levels in the storage medium minimally affect PLT activation. de Wildt-Eggen et al. demonstrated that magnesium and potassium in PAS-2 affected CD62P expression in a concentration-dependent manner; addition of 1.5-4.5 mmol/L MgCl2, 3.0-9.0 mmol/L KCl, or the combination of 1.5 mmol/L MgCl2 and 4.5 mmol/L KCl significantly decreased CD62P expression levels during storage [23] .
Moreover, Diedrich et al. demonstrated that PLTs stored in PAS-containing magnesium and potassium (SSP+) had significantly reduced glycolysis, increased HSR and morphological changes, and lower expression of CD62P and CD63 [24] . In our study, although the magnesium concentrations in the control (0.9 mmol/L) and test (0.5 mmol/L) BRS-As were lower than those in these previous studies, no significant effect on the in vitro properties of PLTs such as CD62P expression, HSR, glucose consumption, and lactate production were detected. The potassium concentrations in the control and test BRS-As were comparable to or lower than those in previous studies [23, 24] . Consequently, these findings suggest that lower concentrations of magnesium and potassium did not cause progressive PLT activation and maintained PLT function when BRS-A was used as a PAS.
In contrast to acetate-free BRS-A, currently reported PASs such as SSP+, Composol, M-sol, and PAS-5, contained acetate in non-physiological concentrations. Saunders et al. reported that addition of acetate to PAS is associated with PLT activation and, paradoxically, reduced ATP levels [25] because the conversion of acetate into acetyl CoA requires ATP [26] . As a PAS constituent, acetate in non-physiological concentrations may promote excessive generation of acetyl CoA and accumulation of pyrophosphate in PLT mitochondria [27] . Although more research is still needed, the storage of PLTs in acetate-free BRS-A may reduce stress and increase PLT functional recovery.
A limitation of this study is that the glucose in BRS-A was depleted by day 5 of storage. One possible reason is the consequence of high rate of glucose consumption due to the absence of acetate in BRS-A and low content of glucose. In fact the glucose consumption rate in PLTs stored in BRS-A was higher than the previous studies of acetate-containing PAS [4, 6] . Glucose deficiency in a storage medium is associated with a decrease in energy production and increase in cell death marker expressions [25] , which were not measured in this study. However, regarding pH, HSR, swirling, and CD62P and CD42b expression, our results showed no considerable variation during 7-day storage. The shelf life of PLT products in Japan is 4 days, and practically storage period of washed PLTs after preparation is 1-3 days. At least glucose remained throughout the period of shelf life in both the storage media.
In Japan, BRS-A was officially described as a washing and replacement solution in the guidelines for washed and replaced PLTs prepared by the Japan Society of Transfusion Medicine and Cell Therapy [12] . The transfusion effect of washed and replaced PLTs with BRS-A will be determined by the measurement of corrected count increment in the study approved by the institutional review board of hospitals. The influence of glucose depletion in storage media on in vivo viability remains to be seen.
Conclusion
Our results demonstrate that BRS-A, a bicarbonatebuffered acetate-free PAS based on two types of BRSs approved for clinical use in Japan, can be successfully applied as a PAS to maintain the in vitro properties of PLTs during 7-day storage. Thus, BRS-A can be used in hospitals that do not stock Bicanate but have Bicarbon.
